Clinical Research Directory
Browse clinical research sites, groups, and studies.
Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan
Sponsor: Shanghai Jiao Tong University School of Medicine
Summary
Conditioning regimen with melphalan-busulfan and fludarabine (MBF) achieved low relapse rate in patients with acute myeloid leukemia (AML) and myelodysplasia syndrome (MDS). In our previous retrospective study, we demonstrated that melphalan dose at 100 or 140mg/m2 had similar incidence of relapse but it might had lower toxicities. In this prospective randomize study, we aim to compare the transplantation outcome in adult patients with AML/MDS receiving either MBF with 100 or 140 mg/m2 melphalan.
Official title: Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomize Study Comparing 100mg/m2 to 140mg/m2 Melphalan for Adult Patients With Acute Myeloid Leukemia or Myelodysplasia Syndrome.
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2023-12-01
Completion Date
2026-12-01
Last Updated
2025-02-17
Healthy Volunteers
No
Conditions
Interventions
melphalan
conditioning regimen with melphalan, busulfan and fludarabine
Locations (2)
Rui Jin Hospital
Shanghai, Shanghai Municipality, China
Zhaxin Hospital, Go Broad Health Care
Shanghai, Shanghai Municipality, China